Upstream Bio (UPB) Total Non-Current Liabilities (2023)
Upstream Bio (UPB) posted quarterly Total Non-Current Liabilities of $6.5 million for Q4 2023.
Powered by 
Analysis
Upstream Bio (UPB) Total Non-Current Liabilities (2023) Analysis & Trends
Upstream Bio's Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $6.5 million for Q4 2023.
- In Q4 2023, Total Non-Current Liabilities changed N/A year-over-year to $6.5 million; the TTM figure through Dec 2023 stood at $6.5 million (changed N/A YoY), while the FY2023 annual figure was $6.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2023 stood at $6.5 million.
- The five-year high for Total Non-Current Liabilities was $6.5 million in Q4 2023, with the low at $6.5 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Upstream Bio | 327.95 Mn | 327.95 Mn | -3.29 Mn | - |